REFERENCES

1. Dhondge RH, Agrawal S, Patil R, Kadu A, Kothari M. A comprehensive review of metabolic syndrome and its role in cardiovascular disease and type 2 diabetes mellitus: mechanisms, risk factors, and management. Cureus 2024;16:e67428.

2. Hamooya BM, Siame L, Muchaili L, Masenga SK, Kirabo A. Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches. Front Nutr 2025;12:1661603.

3. van de Vyver M. Immunology of chronic low-grade inflammation: relationship with metabolic function. J Endocrinol 2023;257:e220271.

4. Islam MS, Wei P, Suzauddula M, et al. The interplay of factors in metabolic syndrome: understanding its roots and complexity. Mol Med 2024;30:279.

5. Shaikh SR, Beck MA, Alwarawrah Y, MacIver NJ. Emerging mechanisms of obesity-associated immune dysfunction. Nat Rev Endocrinol 2024;20:136-48.

6. Wang X, Chen L, Wei J, et al. The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications. Signal Transduct Target Ther 2025;10:166.

7. Yazar S, Alquicira-Hernandez J, Wing K, et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. Science 2022;376:eabf3041.

8. Wang S, Liu S, Zhang H, et al. Integrative functional genomics and fine-mapping identify regulatory mechanisms of multivariate obesity GWAS and its cardiometabolic implications. Metabolism 2026;177:156509.

9. Chami N, Wang Z, Svenstrup V, et al. Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities. Nat Med 2025;31:3801-12.

10. Nathan A, Asgari S, Ishigaki K, et al. Single-cell eQTL models reveal dynamic T cell state dependence of disease loci. Nature 2022;606:120-8.

11. Kim-Hellmuth S, Aguet F, Oliva M, et al. ; GTEx Consortium. Cell type-specific genetic regulation of gene expression across human tissues. Science 2020;369:eaaz8528.

12. Kang JB, Raveane A, Nathan A, Soranzo N, Raychaudhuri S. Methods and insights from single-cell expression quantitative trait loci. Annu Rev Genomics Hum Genet 2023;24:277-303.

13. Gittess D, Thompson I, Traktuev DO, Duarte JD, Keeley EC. Fatty acid desaturase genetic variations in heart failure and cardiovascular disease. Am Heart J Plus 2025;53:100529.

14. Batista LD, Rogero MM, Sarti FM, et al. FADS1 and FADS2 gene polymorphisms affect omega-3 and omega-6 erythrocyte fatty acid composition and influence the association between dietary fatty acid intake and lipid profile in brazilian adults. Metabolites 2025;15:758.

15. Sergeant S, Keith BA, Seeds MC, et al. Impact of FADS gene variation and dietary fatty acid exposure on biochemical and anthropomorphic phenotypes in a Hispanic/Latino cohort. Front Nutr 2023;10:1111624.

16. Hellstrand S, Sonestedt E, Ericson U, et al. Intake levels of dietary long-chain PUFAs modify the association between genetic variation in FADS and LDL-C. J Lipid Res 2012;53:1183-9.

17. Dumont J, Goumidi L, Grenier-Boley B, et al. Dietary linoleic acid interacts with FADS1 genetic variability to modulate HDL-cholesterol and obesity-related traits. Clin Nutr 2018;37:1683-9.

18. Park S, Kim DS, Kang S. Carrying minor allele of FADS1 and haplotype of FADS1 and FADS2 increased the risk of metabolic syndrome and moderate but not low fat diets lowered the risk in two Korean cohorts. Eur J Nutr 2019;58:831-42.

19. Lankinen MA, de Mello VD, Meuronen T, et al. The FADS1 genotype modifies metabolic responses to the linoleic acid and alpha-linolenic acid containing plant oils-genotype based randomized trial FADSDIET2. Mol Nutr Food Res 2021;65:e2001004.

20. Meuronen T, Lankinen MA, Kärkkäinen O, et al. FADS1 rs174550 genotype and high linoleic acid diet modify plasma PUFA phospholipids in a dietary intervention study. Eur J Nutr 2022;61:1109-20.

21. Vaittinen M, Lankinen MA, Käkelä P, et al. The FADS1 genotypes modify the effect of linoleic acid-enriched diet on adipose tissue inflammation via pro-inflammatory eicosanoid metabolism. Eur J Nutr 2022;61:3707-18.

22. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 2020;369:1318-30.

23. Coulson M, Mutch DM. Molecular insights into the functional roles of variants in the FADS gene cluster on omega-3 long-chain polyunsaturated fatty acid synthesis. Lifestyle Genom 2026;19:9-22.

24. Gromovsky AD, Schugar RC, Brown AL, et al. Δ-5 fatty acid desaturase FADS1 impacts metabolic disease by balancing proinflammatory and proresolving lipid mediators. Arterioscler Thromb Vasc Biol 2018;38:218-31.

25. Yuan S, Bäck M, Bruzelius M, Mason AM, Burgess S, Larsson S. Plasma phospholipid fatty acids, FADS1 and risk of 15 cardiovascular diseases: a Mendelian randomisation study. Nutrients 2019;11:3001.

26. Wang Y. Mendelian randomization identifies causal effects of phospholipids on portal vein thrombosis risk: FADS1/2-mediated pathways and their potential as diagnostic biomarkers. Nutr Metab 2026;23:26.

27. Visioli F, Alfredo Martínez J, Tomé-Carneiro J. Genetic modulation of omega-3 and omega-6 polyunsaturated fatty acid metabolism and health outcomes: a systematic review. Food Funct 2026;17:2176-91.

28. Wu JHY, Micha R, Mozaffarian D. Dietary fats and cardiometabolic disease: mechanisms and effects on risk factors and outcomes. Nat Rev Cardiol 2019;16:581-601.